@prefix dcterms: <
http://purl.org/dc/terms/
> .
@prefix ns1: <
http://www.w3.org/ns/prov#
> .
@prefix this: <
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs
> .
@prefix sub: <
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#
> .
@prefix np: <
http://www.nanopub.org/nschema#
> .
@prefix rdf: <
http://www.w3.org/1999/02/22-rdf-syntax-ns#
> .
@prefix nt: <
https://w3id.org/np/o/ntemplate/
> .
@prefix xsd: <
http://www.w3.org/2001/XMLSchema#
> .
@prefix rdfs: <
http://www.w3.org/2000/01/rdf-schema#
> .
@prefix orcid: <
https://orcid.org/
> .
@prefix bl: <
https://w3id.org/biolink/vocab/
> .
@prefix nkg: <
https://w3id.org/um/neurodkg/
> .
@prefix npx: <
http://purl.org/nanopub/x/
> .
sub:Head
{
this:
np:hasAssertion
sub:assertion
;
np:hasProvenance
sub:provenance
;
np:hasPublicationInfo
sub:pubinfo
;
a
np:Nanopublication
.
}
sub:assertion
{
<
http://purl.obolibrary.org/obo/DOID_11199
>
bl:category
bl:Disease
.
sub:association
rdf:object
<
http://purl.obolibrary.org/obo/DOID_11199
> ;
rdf:predicate
bl:treats
;
rdf:subject
<
https://identifiers.org/drugbank:DB00136
> ;
a
rdf:Statement
;
rdfs:label
"predialysis patients calcitriol oral solution is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure ccr 15 to 55 ml min not yet on dialysis in children the creatinine clearance value must be corrected for a surface area of 1 73 square meters a serum ipth level of 1 pg ml is strongly suggestive of secondary hyperparathyroidism dialysis patients calcitriol oral solution is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis in these patients calcitriol oral solution administration enhances calcium absorption reduces serum alkaline phosphatase levels and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization hypoparathyroidism patients calcitriol oral solution is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism idiopathic hypoparathyroidism and pseudohypoparathyroidism" ;
bl:association_type
bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation
;
bl:provided_by
<
https://w3id.org/um/NeuroDKG
> ;
bl:relation
nkg:SymptomaticReliefIndication
.
<
https://identifiers.org/drugbank:DB00136
>
bl:category
bl:Drug
.
}
sub:provenance
{
sub:assertion
ns1:wasAttributedTo
orcid:0000-0002-1468-3557
.
}
sub:pubinfo
{
sub:sig
npx:hasAlgorithm
"RSA" ;
npx:hasPublicKey
"MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" ;
npx:hasSignature
"Qa9CCDGxt0tiC2GborRIpO8j1+HdNNlOz0WOl14qSvVku8CujA9oWO4BVs/9+3hLEbIiIQ4+pG1gaprTtwAPdehJN3fb890+h1G3w/twuK/i85W/Len3Z2x5py6S9PM8OxIHYXWyOC9CGlIKvGZ395GB8k67y/oZYs9Lh6tAdNc=" ;
npx:hasSignatureTarget
this:
.
this:
dcterms:created
"2021-07-03T12:15:58.917+02:00"^^
xsd:dateTime
;
dcterms:creator
orcid:0000-0002-1468-3557
;
nt:wasCreatedFromProvenanceTemplate
<
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
> ;
nt:wasCreatedFromPubinfoTemplate
<
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
> ;
nt:wasCreatedFromTemplate
<
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs
> .
}